Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells

References

• Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431–436.
   PubMed Web of Science ®Google Scholar
• Peng HL, Zhang GS, Liu JH, et al. Dup-697, a specific COX-2 inhibitor, suppresses growth and induces apoptosis on K562 leukemia cells by cell-cycle arrest and caspase-8 activation. Ann Hematol 2008;87:121–129.
   PubMed Web of Science ®Google Scholar
• Murata H, Tsuji S, Tsujii M, et al. Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells. Lab Invest 2004;84:1050–1059.
   PubMed Web of Science ®Google Scholar
• McGinty A, Chang YW, Sorokin A, et al. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem 2000;275:12095–12101.
   PubMed Web of Science ®Google Scholar
• Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003;7:207–222.
   PubMed Web of Science ®Google Scholar
• Cianchi F, Cortesini C, Fantappie O, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004;10:2694–2704.
   PubMed Web of Science ®Google Scholar
• Krysan K, Merchant FH, Zhu L, et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer. FASEB J 2004;18:206–208.
   PubMed Web of Science ®Google Scholar
• Krysan K, Dalwadi H, Sharma S, et al. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004;64:6359–6362.
   PubMed Web of Science ®Google Scholar
• Hashitani S, Urade M, Nishimura N, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 2003;23:665–672.
   PubMed Web of Science ®Google Scholar
• Chen WS, Liu JH, Liu JM, et al. Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells. Anticancer Drugs 2004;15:287–294.
   PubMed Web of Science ®Google Scholar
• Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003;21:2645–2650.
   PubMed Web of Science ®Google Scholar
• Komaki R, Liao Z, Milas L. Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 2004;31:47–53.
   PubMed Web of Science ®Google Scholar
• Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005;65:9501–9509.
   PubMed Web of Science ®Google Scholar
• Liao Z, Milas L, Komaki R, et al. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 2003;26:S85–S91.
   PubMed Web of Science ®Google Scholar
• Bernard MP, Bancos S, Sime PJ, et al. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 2008;14:2051–2060.
   PubMed Web of Science ®Google Scholar
• Chen C, Shen HL, Yang J, et al. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxb,. J Cancer Res Clin Oncol 2011;137:9–17.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Barbarotto E, Gonelli A, et al. Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells. Am J Pathol 2005;167:1599––1607.
   PubMed Web of Science ®Google Scholar
• Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004;28:179–190.
   PubMed Web of Science ®Google Scholar
• Zhang GS, Liu DS, Dai CW, et al. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 2006;81:242–255.
   PubMed Web of Science ®Google Scholar
• Puhlmann U, Ziemann C, Ruedell G, et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 2005;312: 346–354.
   PubMed Web of Science ®Google Scholar
• Dandekar DS, Lopez M, Carey RI, et al. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005;115:484–492.
   PubMed Web of Science ®Google Scholar
• Jeong J, Verheyden JM, Kimble J. Cyclin E and Cdk2 control GLD-1, the mitosis/meiosis decision, and germline stem cells in Caenorhabditis elegans. PLoS Genet 2011;7:e1001348.
   PubMed Web of Science ®Google Scholar
• Kuo PC, Liu HF, Chao JI. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J Biol Chem 2004;279:55875–55885.
   PubMed Web of Science ®Google Scholar
• Lu B, Mu Y, Cao C, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004;64: 2840–2845.
   PubMed Web of Science ®Google Scholar
• Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001;7:542–547.
   PubMed Web of Science ®Google Scholar